Drugs / AB8939
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05211570 | Jun 2022 → Aug 2026 overdue | acute myeloid leukemia, myelodysplastic syndrome | AB Science | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 19
| Date | Issuer | Release |
|---|---|---|
| 2026-06-29 | AB Science | Results AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML ab-science.com ↗ |
| 2026-01-07 | AB Science | Results AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia ab-science.com ↗
Under the AB8939 + venetoclax combination, the patient achieved a partial response. |
| 2025-12-15 | AB Science | Results AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers ab-science.com ↗
AB8939 has dual action against both proliferating tumor c ells (via tubulin disruption) and quiescent, resistant stem cells (via ALDH inhibition) making it a unique therapeutic agent |
| 2025-10-16 | AB Science | Results Summary of the virtual conference held on October 16, 2025 ab-science.com ↗
The disease control rate is 100% (3/3) and the partial response rate is 100% (3/ 3), including one patient in complete remission |
| 2025-10-16 | AB Science | Results AB Science webcast of October 16, 2025 ab-science.com ↗
Response evaluation D28 Partial remission (PR) |
| 2025-10-14 | AB Science | Results AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939 ab-science.com ↗
The partial response rate is 100% (3/3), including one patient in complete remission |
| 2025-07-30 | AB Science | Regulatory AB Science receives regulatory approval from european countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML ab-science.com ↗ |
| 2025-06-12 | AB Science | Regulatory AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036 ab-science.com ↗
AB Science SA (Euronext - FR0010557264 - AB) today announced that the patent office of Canada has granted a patent (CA 2975644) protecting the composition of matter of AB8939, and closely related compounds, until 2036. |
| 2025-04-23 | AB Science | Regulatory European Medicines Agency has granted orphan drug designation in the European Union for AB8939 in the treatment of acute myeloid leukemia ab-science.com ↗
AB Science SA (Euronext - FR0010557264 - AB) announces today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia (AML). |
| 2024-12-17 | AB Science | Results Summary of the webcast held on December 16, 2024 ab-science.com ↗
AB8939 has shown a signal of efficacy in AML with MECOM gene rearrangement, a subset of pa tients that show extreme resistance to chemotherapies and exhibit the worst survival prognosis |
| 2024-12-16 | AB Science | Results AB Science webcast of December 16, 2024 ab-science.com ↗
Preliminary evidence indicate 50% response rate with AB8939 single agent |
| 2024-09-26 | AB Science | Results AB Science provides an update on the microtubule program AB8939 ab-science.com ↗ |
| 2023-03-13 | AB Science | Results AB Science reports a first complete bone marrow response in a relapsed refractory acute myeloid leukemia patient from the very low dose arm of its AB8939 Phase I/II clinical trial (AB18001) ab-science.com ↗
One month after the first treatment cycle (i.e., three consecutive days of AB8939 treatment) there was a drastic reduction in bone marrow blast cells (i.e., leukemia cells), from a pretreatment lev el of 55% to 5% (i.e., a morphologic leukemia free state) . |
| 2021-11-22 | AB Science | Regulatory AB Science received FDA authorization to initiate Phase 1/II trial of AB8939 in the treatment of acute myeloid leukemia ab-science.com ↗
AB SCIENCE RECEIVES U.S. FOOD AND DRUG ADMINISTRATION (FDA) AUTHORIZATION TO INITIATE PHASE I/II TRIAL OF AB8939 IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) |
| 2021-10-18 | AB Science | Regulatory AB Science granted authorization from the French Health Authority (ANSM) to initiate a study of AB8939 in the treatment of Acute Myeloid Leukemia (AML) ab-science.com ↗ |
| 2021-09-22 | AB Science | Regulatory AB Science receives Health Canada approval letter to commence Phase I/II trial of AB8939 in the treatment of Acute Myeloid Leukemia ab-science.com ↗ |
| 2019-11-07 | AB Science | Regulatory AB8939 receives Orphan Drug Designation for Acute Myeloid Leukemia from FDA ab-science.com ↗
07/11/2019 – AB Science announces that AB8939 receives Orphan Drug Designation for Acute Myeloid Leukemia from FDA |
| 2019-11-06 | AB Science | Results First presentation of preclinical results for compound AB8939 in the 61st ASH Annual Meeting ab-science.com ↗
06/11/2019 – AB Science announces the first presentation of preclinical results of compound AB8939 in the 61st ASH Annual meeting online program |
| 2019-07-04 | AB Science | Regulatory Validation of the AB8939 clinical development plan through regulatory authority Scientific Advice procedure ab-science.com ↗
AB Science announces the European Medicine Agency has validated the clinical development program for its new compound AB8939 in acute myeloid leukemia (AML) through a Scientific Advice procedure. |
All press releases naming this drug 21 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AB8939 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05211570 ↗ |
| Modality | Small molecule | — CHEMBL5095208 ↗ |
| Route | Intravenous | “Intravenous injection (from an initial dose of 0.9 mg/m²)” NCT05211570 ↗ |